Control Bionics Ltd
ASX:CBL
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Control Bionics Ltd
Cost of Revenue
Control Bionics Ltd
Cost of Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cost of Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Control Bionics Ltd
ASX:CBL
|
Cost of Revenue
-AU$2m
|
CAGR 3-Years
-1%
|
CAGR 5-Years
-23%
|
CAGR 10-Years
N/A
|
|
|
Somnomed Ltd
ASX:SOM
|
Cost of Revenue
-AU$47.6m
|
CAGR 3-Years
-17%
|
CAGR 5-Years
-16%
|
CAGR 10-Years
-10%
|
|
|
Cochlear Ltd
ASX:COH
|
Cost of Revenue
-AU$636.9m
|
CAGR 3-Years
-15%
|
CAGR 5-Years
-13%
|
CAGR 10-Years
-8%
|
|
|
Optiscan Imaging Ltd
ASX:OIL
|
Cost of Revenue
-AU$409.1k
|
CAGR 3-Years
49%
|
CAGR 5-Years
2%
|
CAGR 10-Years
N/A
|
|
|
Austco Healthcare Ltd
ASX:AHC
|
Cost of Revenue
-AU$44m
|
CAGR 3-Years
-33%
|
CAGR 5-Years
-26%
|
CAGR 10-Years
N/A
|
|
|
EMvision Medical Devices Ltd
ASX:EMV
|
Cost of Revenue
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Control Bionics Ltd
Glance View
Control Bionics Ltd. engages in the manufacture, design, and sale of wireless wearable electromyography (EMG) based augmentative and alternative communication (AAC) technology. The company is headquartered in Sydney, New South Wales. The company went IPO on 2020-12-07. The firm is principally engaged in development, commercialization and sale of assistive communications technology systems namely NeuroNode within the disability sector. The Group’s core systems include NeuroNode Trilogy and NeuroNode3. These systems allow people with speech and movement difficulties to control a computer for speech generation, electronic communications, entertainment and external control of other devices. Its NeuroNode Trilogy system combines its NeuroNode with eye-gaze technology to create a communication system. Its NeuroNode3 combines the NeuroNode wearable device with operating systems and is suitable for users with severe impairment. Its geographical locations consist of Australia, which is engaged in sales of Trilogy units and components in Australia, and North America, which is engaged in manufacturing and sales of Trilogy units and components in North America.
See Also
What is Control Bionics Ltd's Cost of Revenue?
Cost of Revenue
-2m
AUD
Based on the financial report for Jun 30, 2025, Control Bionics Ltd's Cost of Revenue amounts to -2m AUD.
What is Control Bionics Ltd's Cost of Revenue growth rate?
Cost of Revenue CAGR 5Y
-23%
Over the last year, the Cost of Revenue growth was -40%. The average annual Cost of Revenue growth rates for Control Bionics Ltd have been -1% over the past three years , -23% over the past five years .
